The medicines cost-effectiveness watchdog for England and Wales has today published draft updated guidance recommending National Health Service use of US biotech firm Celgene’s (Nasdaq: CELG) Otezla (apremilast) for psoriatic arthritis.
This appraisal was a rapid review of the National Institute for Health and Care Excellence (NICE) technology appraisal guidance published in December 2015. It focused on cost-effectiveness analyses using a patient access scheme agreement, which provides apremilast at a reduced cost. The discount is commercial in confidence.
The appraisal committee noted that the base-case incremental cost-effectiveness ratio (ICER) with the patient access scheme was £39,052 ($48,659) saved per quality-adjusted life-year (QALY) lost. All exploratory analyses presented by both the company and the ERG also showed that using apremilast resulted in cost savings but a QALY loss.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze